Tamoxifen: a most unlikely pioneering medicine

@article{Jordan2003TamoxifenAM,
  title={Tamoxifen: a most unlikely pioneering medicine},
  author={V. Jordan},
  journal={Nature Reviews Drug Discovery},
  year={2003},
  volume={2},
  pages={205-213}
}
  • V. Jordan
  • Published 2003
  • Medicine
  • Nature Reviews Drug Discovery
For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization lists tamoxifen as an essential drug for the treatment of breast cancer. It is estimated that more than 400,000 women are alive today as a result of tamoxifen therapy, and millions more have benefited from palliation and extended disease-free survival. Interestingly, tamoxifen also became the first cancer… Expand
Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.
  • V. Jordan
  • Medicine
  • Endocrine-related cancer
  • 2014
TLDR
This success story is that success story, with a focus on the interdependent components of: excellence in drug discovery, investment in self-selecting young investigators, conversation with Nature, a conversation between the laboratory and the clinic, and the creation of the Oxford Overview Analysis. Expand
Tamoxifen: catalyst for the change to targeted therapy.
  • V. Jordan
  • Medicine
  • European journal of cancer
  • 2008
TLDR
Overall, the rigorous investigation of the pharmacology of tamoxifen facilitated tamoxIFen's ubiquitous use for the targeted treatment of breast cancer, chemoprevention and pioneered the exploration of selective oestrogen receptor modulators (SERMs). Expand
Problems with the progesterone receptor in practice?
  • V. Jordan, R. Gelber
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The authors found that patients whose tumors are ER /PgR are more likely to benefit from an additional 5 years of letrozole than are those with ER / PgR tumors, and Laboratory studies suggest that when drug resistance develops during long-term tamoxifen treatment and treatment is stopped, the undetected nascent tumors will still respond to either estrogen or tamoxIFen for growth. Expand
Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
TLDR
The role of Tamoxifen in breast cancer treatment including mechanisms and side-effects are focused on, and the exciting prospects that lie ahead are discussed. Expand
Adherence to long-term adjuvant hormonal therapy for breast cancer
  • C. Gotay, J. Dunn
  • Medicine
  • Expert review of pharmacoeconomics & outcomes research
  • 2011
TLDR
The most recent literature reporting adherence rates for tamoxifen and AIs, as well as correlates of adherence are reviewed, including the side-effect profile, and approaches to intervention to enhance adherence are discussed. Expand
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
TLDR
This minireview will describe the current strategies for the treatment and prevention of breast cancer and present emerging new concepts about the consequences of exhaustive antiestrogen treatment on therapeutic resistance. Expand
Optimizing the antihormonal treatment and prevention of breast cancer
TLDR
The therapeutic options for anti-hormonal therapy, the role of anti-Hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators are summarized. Expand
SERMs: meeting the promise of multifunctional medicines.
  • V. Jordan
  • Medicine
  • Journal of the National Cancer Institute
  • 2007
The successful development and clinical evaluation of the selective estrogen receptor modulators in the Study of Tamoxifen and Raloxifene trial provides an occasion to reflect on the milestone thatExpand
Precision Medicine in Hormone Receptor-Positive Breast Cancer
TLDR
The opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer are discussed. Expand
Oestrogens, Oestrogen Receptors and Breast Cancer
TLDR
Raloxifene is the result of this new strategy to seek multifunctional medicines for women's health and is currently available for the treatment and prevention of osteoporosis but is being tested in high-risk postmenopausal women for the prevention of breast cancer against tamoxifen. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 133 REFERENCES
Tamoxifen (antiestrogen) therapy in advanced breast cancer.
TLDR
Tumors containing estrogen receptors and those that responded to previous hormonal manipulation tended to respond to tamoxifen (antiestrogen), 60% and 69%, respectively, and patients with receptor-negative tumor or with a history of failure of previous hormonal treatments did not respond. Expand
The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole
  • V. Jordan
  • Medicine
  • Breast Cancer Research and Treatment
  • 2005
SummaryTamoxifen, a nonsteroidal antiestrogen, is now the endocrine treatment most widely used in breast cancer, both in the adjuvant and advanced disease settings. Here we will trace the developmentExpand
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
TLDR
The frequency of new primary cancers was studied in 1846 postmenopausal patients included in a randomised trial of tamoxifen as an adjunct to primary surgery for early breast cancer and the increase in endometrial cancers was most pronounced in those treated for over 2 years. Expand
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
TLDR
The authors have been unable to show any effect of tamoxifen on breast-cancer incidence in healthy women, contrary to the report from the NSABP-P1 study showing a 45% reduction inhealthy women given tamoxIFen versus placebo. Expand
A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.
TLDR
Results of this pilot trial of tamoxifen, an anti-oestrogen, compared to placebo given to 200 women at a high risk of developing breast cancer show that acute toxicity is low and that accrual and compliance are satisfactory, and biochemical monitoring of lipids and clotting factors indicate that tamoxify may reduce the risk of cardiovascular deaths. Expand
Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels
  • H. Ward
  • Medicine
  • British medical journal
  • 1973
Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumourExpand
Tamoxifen and contralateral breast cancer.
TLDR
In this review, the available data on tamoxifen and CBC are examined and the secondary neoplasms are attempted to characterize, such that 1 year, 2 years, and 5 years of treatment are associated with risk reductions of 13%, 26%, and 47%, respectively. Expand
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
TLDR
Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease. Expand
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
TLDR
Anastrozole is an effective and well tolerated endocrine option for the treatment of postmenopausal patients with hormone-sensitive early breast cancer and longer follow-up is required before a final benefit:risk assessment can be made. Expand
Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.
TLDR
Since there was no statistically significant difference in efficacy and since tamoxifen was less toxic, tamoxIFen appears to be the preferred agent. Expand
...
1
2
3
4
5
...